双表达性淋巴瘤的最新进展:新的治疗方法和前景
Yuejian Zhuo1, Dongdong Zhang1
1Department of Oncology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China.
The oncologist
|June 17, 2025
概括
双表达性淋巴瘤 (DEL) 是扩散性大B细胞淋巴瘤 (DLBCL) 的一种亚型,具有BCL2和MYC过度表达,预后较差. 本综述探讨了DEL的新兴治疗方法和临床数据,并提供基于证据的建议.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 双表达性淋巴瘤 (DEL) 是扩散性大B细胞淋巴瘤 (DLBCL) 的一个独特的亚型.
- 德尔的特点是BCL2和MYC蛋白的共同过度表达.
- 这种亚型主要与激活的B细胞样 (ABC) DLBCL相关,预后较差.
研究的目的:
- 审查治疗DEL的新兴药物和临床试验数据.
- 为DEL制定基于证据的治疗建议.
- 为临床DEL管理提供理论基础.
主要方法:
- 新兴药物的文献综述和临床试验数据.
- 分析导致DEL预后不佳的因素.
- 基于证据的治疗建议的制定.
主要成果:
- 德尔病例往往呈现出晚期和高风险的预后得分.
- 在DEL中同时BCL2和MYC过度表达与不利的结果相关.
- 与其他DLBCL亚型相比,标准化疗免疫疗法在DEL中显示出有限的疗效.
结论:
- 德尔需要量身定制的治疗策略,超出标准化疗免疫疗法.
- 新兴的向疗法和临床试验为改善DEL治疗提供了潜力.
- 进一步的研究和临床评估对于优化DEL管理至关重要.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)

